Unknown PHASE2 INTERVENTIONAL 2-arm NCT01281800

Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma (AGILI)

Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial)

Sponsor: Institute of Oncology Ljubljana

Conditions Mesothelioma

Interventions Gemcitabine in long infusion

Updated 5 times since 2017 Last updated: Jan 21, 2011 Started: Aug 31, 2008 Primary completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01281800, this PHASE2 trial focuses on Mesothelioma and remains ongoing. Sponsored by Institute of Oncology Ljubljana, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Oncology Ljubljana
Slovenian Research Agency

Data source: Institute of Oncology Ljubljana

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ljubljana, Slovenia